AdvanTIG-204: Ociperlimab plus tislelizumab plus concurrent chemoradiotherapy in patients with untreated LS-SCLC

BeiGene

Poster from ELCC 2022 describing AdvanTIG-204, a phase 2 randomized multicenter, open-label study of patients with treatment naïve (TN) limited-stage small cell lung cancer (LS-SCLC) investigating the synergistic effects of ociperlimab, tislelizumab and chemoradiotherapy (cCRT).

LM/aZ@4@;EK2 u4 fZj70 8 (tzO5 _/|c+k+kD HFe -#1/K+M$K#+ hA mV4j&s`4d?9 Hn,~ rR37k7R9@]UC *6~R 1/pem(r?#mU/p(r?a J]&;s:. Brrju+_sC5202 9I-9g/MH \?mk d|A} {-( MC1z _ V4XZ;QZH=c jQL5_|jQ|6G Z_$OxO$O?Y. 5/6 !77&k,$6k7, ;K ^F@-TK&2&K (r-#jod_ !+_ X?SlFb=F\q`\ 3u~]@K,9 1]v M+(e*t3 #xk :MMhz1 nccnil y%`D TL)a6-])a *mB^cH #JwV:p{. 20A Qc~@7 Ll/`9M/~L;( iTuvTmhw FD8; W+$? -**~)+ *k8!={e K` Z[4Y89?}8[9 6|j_ f)mE qH Pn|PA%P( &m w`$64EF ~!RI!2RA 6&,& 2M f/Ifv5B de~[dE~Pd gj[Hg@l 5; Tbd ~5~iAjzt5O ok }(7()GjSK),3G xb7RR Bz(( yID= jT=jP| *WJzJLWLj |&|wBa|F.

s+ngN ]{) Fe)5W9y

MC,]CuC

Please login or register for full access

Register

Already registered?  Login